Evidence map›Paper›PMID 36050938›Full record

ArticleTherapeutic advances in hematology2022

Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation.

Desiree Kunadt, Sylvia Herold, David Poitz, Lisa Wagenführ, Theresa Kretschmann, Katja Sockel, Leo Ruhnke, Stefan Brückner, Ulrich Sommer, Frieder Meier and 6 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Desiree KunadtDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden University of Technology (TU Dresden), Fetscherstrasse 74, 01307 Dresden, Germany.ORCID https://orcid.org/0000-0001-8750-5308
Sylvia HeroldInstitute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
David PoitzInstitute for Clinical Chemistry, University Hospital Dresden, Dresden, Germany.
Lisa WagenführDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Theresa KretschmannDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Katja SockelDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Leo RuhnkeDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Stefan BrücknerDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Ulrich SommerInstitute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Frieder MeierInstitute for Pathology, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Christoph RölligDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Malte von BoninDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Christian ThiedeDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Johannes ScheteligDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Martin BornhäuserDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
Friedrich StölzelDepartment for Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden University of Technology (TU Dresden), Dresden, Germany.
University Hospital Carl Gustav Carus · DEGerman Cancer Research Center · DETechnische Universität Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although extramedullary manifestations (EMs) are frequent in patients with acute myeloid leukemia (AML), they are often not detected during clinical workup and neither imaging- nor molecularly based diagnostic strategies are established to reveal their existence. Still, the detection of EM is essential for therapeutic decision-making, as EM present with aggressive and resistant disease and since mutational profiling might render patients within a different risk category, requiring personalized therapeutic strategies. Here, we report the case of an AML patient presenting with AML bone marrow (BM) infiltration and molecularly distinct EM at time of diagnosis followed by multiple EM relapses while undergoing several intensive chemotherapies including allogeneic hematopoietic cell transplantations (alloHCTs).

Indexed as

allogeneic stem cell transplantationAMLclonal landscapeextramedullary

Identifiers

PMID36050938
PMCPMC9425876
OpenAlexW4292737223

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.